1607658587_ISOOQg_2020_12_10T190455Z_3_LYNXMPEGB91LH_RTROPTP_4_HEALTH_CORONAVIRUS_BRITAIN_VACCINE.JPG 
Gennova Biopharmaceuticals had first submitted the vaccine data in the month of April with additional data in May. The indiginous innovative mRNA vaccine can be kept under 2 to 8 degree celsius while most other vaccines have to be stored at sub zero temperatures
Photo Credit :
The Covid working group of the National Technical Advisory Group On Immunisation is likely to meet to discuss India’s first mRNA vaccine against Covid and the booster dose for Covishield and Covaxin recipients developed by Biological E’s.
The Drugs Controller General of India (SCGI) recently cleared the 2 dose mRNA vaccine of Gennova Biopharmaceuticals for restricted use in emergency scenarios against Covid for the age group of 18 above.
Gennova Biopharmaceuticals had first submitted the vaccine data in the month of April with additional data in May. The indiginous innovative mRNA vaccine can be kept under 2 to 8 degree celsius while most other vaccines have to be stored at sub zero temperatures.
The vaccine is based on the second wave driven delta variant. On Friday, the Subject Expert Committee found the mRNA vaccine data provided by Gennova Biopharmaceuticals as satisfactory.